TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2021

Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study.

Steven R Feldman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.